Expensify, Inc.
NASDAQ:EXFYSoftware - Application
+$0.35 today
- Market cap
- $157.19M
- Beta
- 1.80
- P/E (TTM)
- -7.0
- EPS (TTM)
- -$0.22
Volume 0.63M
Average 0.79M
EXFY Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Expensify, Inc.NASDAQ: EXFY
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development declines year over year
Q1 FY2026 research & development of $5.27M fell 1.7% year over year, ahead of the -6.6% change in trailing-twelve-month research & development. Sequentially, it rose 0.1% from the prior quarter. Over 3 fiscal years it compounded at +14.7% a year.
Context
- Research & development amounted to 14.6% of revenue in FY2025, down 3.1 pp from a year earlier.
- Research & development increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of -1.7% holds above the trailing-twelve-month pace of -6.6%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 20.68M USD
- Year-over-year change
- -16.1%
- 4-year CAGR
- +17.1%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 20.68M | -16.1% |
| FY2024 | 2024-12-31 | 24.64M | +5.4% |
| FY2023 | 2023-12-31 | 23.37M | +70.7% |
| FY2022 | 2022-12-31 | 13.69M | +24.6% |
| FY2021 | 2021-12-31 | 10.99M | — |
Research & Development vs competitors
How EXFY compares with its peers on the latest reported figures
- EXFY's LTM Mar 2026 research & development of $22.49M is the 5th highest of the 10 companies compared; the peer median is $19.86M.
- Its year-over-year change of -6.6% is the 7th highest of 8, against a peer median of +19.2%.
- Research & development amounts to 16.1% of revenue for EXFY, versus a peer median of 11.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $3.92B | +138436.6% | +847.6% | 24236.6% | |
TEADTeads Holding Co. | LTM Mar 2026 | $40.26M | -3.8% | +2.6% | 3.1% |
SVCOSilvaco Group, Inc. Common Stock | LTM Mar 2026 | $33.82M | +54.3% | +33.9% | 50.7% |
| LTM Mar 2026 | $30.29M | +19.2% | +12.8% | 8.4% | |
| LTM Mar 2026 | $22.49M | -6.6% | +14.7% | 16.1% | |
| LTM Mar 2026 | $19.86M | — | — | 11.0% | |
| LTM Mar 2026 | $16.21M | +12.3% | +16.5% | 16.2% | |
| LTM Mar 2026 | $10.08M | +61.6% | +36.9% | 54.3% | |
HITHealth In Tech, Inc. | LTM Mar 2026 | $1.95M | -24.7% | +25.5% | 5.7% |
| FY2025 | $0 | — | — | 0.0% | |
| Peer median (excluding EXFY) | $19.86M | +19.2% | +25.5% | 11.0% | |
Competitors are the stored peer set for EXFY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 142.84M | 169.5M | 150.69M | 139.24M | 142.1M |
| Cost of Revenue | 53.69M | 62.67M | 66.89M | 64.24M | 70.57M |
| Gross Profit | 89.14M | 106.83M | 83.8M | 75M | 71.53M |
| Gross Margin | 62.4% | 63.0% | 55.6% | 53.9% | 50.3% |
| Research & Development | 10.99M | 13.69M | 23.37M | 24.64M | 20.68M |
| Selling, General & Admin | 88.41M | 108.37M | 93.58M | 51.18M | 68.86M |
| Operating Expenses | 99.39M | 122.06M | 116.95M | 75.82M | 89.55M |
| Depreciation & Amortization | 5.2M | 6.05M | 5.16M | 6.81M | 8.46M |
| EBITDA | (5.06M) | (9.18M) | (27.99M) | 5.99M | (7.83M) |
| EBITDA Margin | -3.5% | -5.4% | -18.6% | 4.3% | -5.5% |
| Operating Income | (10.25M) | (15.23M) | (33.15M) | (820K) | (18.02M) |
| Operating Margin | -7.2% | -9.0% | -22.0% | -0.6% | -12.7% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 3.48M | 5.41M | 5.33M | 1.57M | 0 |
| Other Income / Expenses | (3.48M) | (5.41M) | (5.33M) | (1.57M) | 1.73M |
| Income Before Tax | (13.73M) | (20.64M) | (38.48M) | (2.39M) | (16.29M) |
| Pre-Tax Margin | -9.6% | -12.2% | -25.5% | -1.7% | -11.5% |
| Income Tax Expense | (174K) | 6.37M | 2.98M | 7.66M | 5.1M |
| Net Income | (13.56M) | (27.01M) | (41.46M) | (10.06M) | (21.39M) |
| Net Margin | -9.5% | -15.9% | -27.5% | -7.2% | -15.1% |
| EPS (Basic) | (0.17) | (0.33) | (0.50) | (0.12) | (0.23) |
| EPS (Diluted) | (0.17) | (0.33) | (0.50) | (0.12) | (0.23) |
| Weighted Avg Shares | 81.4M | 80.79M | 82.49M | 87.38M | 92.28M |
| Weighted Avg Shares (Diluted) | 81.4M | 80.79M | 82.49M | 87.38M | 92.28M |
Expensify, Inc.
NASDAQ:EXFY
Intrinsic Alpha fair value
Locked
Current Price
$1.63
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.